Intracellular Th — Company Overview, News & Financial Data

Intracellular Therapies (NASDAQ:ITCI) is a biopharmaceutical company focused on the development and commercialization of therapies for patients with neuropsychiatric and neurologic disorders, including schizophrenia and depression. Intracellular Therapies aims to leverage its expertise in the science of intracellular signaling to bring forward novel, efficacious treatments that improve patients' lives. Key projects include the continued development and marketing of CAPLYTA® (lumateperone) for schizophrenia and bipolar depression, along with an expanding pipeline of innovative compounds in various stages of clinical development. The company's objectives center around advancing research and development in central nervous system disorders, with a commitment to uncovering breakthrough therapies that can address unmet medical needs in mental health and neurological conditions.